Skip to content
value.today

Arbor Biotechnologies, Inc.

Total raised
$231 M
2 rounds on record
Latest round
$215 M
Oct 2021
First round on record
May 2017
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Arbor Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2021$215 MNo. 2$50 to $250 million

Arbor Biotechnologies, Inc.: Raise no. 2, Oct 2021

Investors in this round

37 investors had bought by the notice of Nov 10, 2021: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$215 M of $215 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Cheng · Executive Officer
  • Devyn Smith · Executive Officer, Director
  • John Murphy · Executive Officer
  • Kelly Morgan · Executive Officer
  • Pam Stetkiewicz · Executive Officer
  • Chen Yu · Director
  • David Walt · Director
  • Keith Crandell · Director
  • Mark Angelino · Director
  • Paul Meister · Director
  • Rami Harawi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Devyn Smith, Chief executive officer. Source: SEC Form D, newest notice filed Nov 10, 2021. Read the notice at the SEC.

equitySEC
May 2017$16 MNo. 1$10 to $50 million

Arbor Biotechnologies, Inc.: Raise no. 1, May 2017

Investors in this round

10 investors had bought by the notice of Aug 2, 2017: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Arthur Scott · Executive Officer
  • Winston Xia Yan · Executive Officer
  • Annie Xia Hazlehurst · Director
  • David R. Walt · Director
  • Feng R. Zhang · Director
  • Keith Xia Crandell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Winston Yan, Secretary and treasurer. Source: SEC Form D and 1 amendment, newest notice filed Aug 2, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Arbor Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2021).

    SEC Form D · Nov 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2021

That is all the official record says: Arbor Biotechnologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Arbor Biotechnologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 37 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arbor Biotechnologies, Inc.
NameRoleNamed in
David ChengExecutive officerNov 2021
Devyn SmithExecutive officerNov 2021
John MurphyExecutive officerNov 2021
Kelly MorganExecutive officerNov 2021
Pam StetkiewiczExecutive officerNov 2021
David Arthur ScottExecutive officerAug 2017
Winston Xia YanExecutive officerAug 2017
Chen YuDirectorNov 2021
David WaltDirectorNov 2021
Devyn SmithDirectorNov 2021
Keith CrandellDirectorNov 2021
Mark AngelinoDirectorNov 2021
Paul MeisterDirectorNov 2021
Rami HarawiDirectorNov 2021
Annie Xia HazlehurstDirectorAug 2017
David R. WaltDirectorAug 2017
Feng R. ZhangDirectorAug 2017
Keith Xia CrandellDirectorAug 2017